ID   NCI-H2373
AC   CVCL_A533
SY   H2373; H-2373; NCIH2373
DR   EFO; EFO_0006679
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-5943
DR   BioSample; SAMN03471008
DR   BioSample; SAMN03472607
DR   BioSamples; SAMEA100828
DR   cancercelllines; CVCL_A533
DR   Cell_Model_Passport; SIDM00103
DR   Cosmic; 886391
DR   Cosmic; 1032375
DR   Cosmic; 1522781
DR   Cosmic; 1541217
DR   Cosmic; 2759213
DR   Cosmic-CLP; 1290809
DR   DepMap; ACH-002124
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 1290809
DR   GEO; GSM726265
DR   GEO; GSM850300
DR   GEO; GSM1669819
DR   PharmacoDB; NCIH2373_1089_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_A533
DR   Wikidata; Q54907969
RX   PubMed=7695406;
RX   PubMed=8806092;
RX   PubMed=11030152;
RX   PubMed=16630136;
RX   PubMed=21245096;
RX   PubMed=21642991;
RX   PubMed=23830731;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26011428;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28553954;
RX   PubMed=30894373;
RX   PubMed=31803961;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   HLA typing: A*02:01,30:01; B*41:01,55:01; C*03:03,17:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136; PubMed=21642991).
CC   Sequence variation: Gene deletion; HGNC; 7773; NF2; Zygosity=Homozygous (PubMed=16630136).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.63%; Native American=0%; East Asian, North=0%; East Asian, South=0.91%; South Asian=2.63%; European, North=66.33%; European, South=29.5% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-5943; true.
CC   Derived from site: In situ; Lung, pleura; UBERON=UBERON_0000977.
ST   Source(s): ATCC; Cosmic-CLP; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 9,12
ST   D16S539: 12
ST   D18S51: 17
ST   D21S11: 30
ST   D3S1358: 16,18
ST   D5S818: 11,13
ST   D7S820: 8,11
ST   D8S1179: 12,15
ST   FGA: 19,22
ST   Penta D: 12
ST   Penta E: 5,11
ST   TH01: 9.3,10
ST   TPOX: 8
ST   vWA: 14 (Cosmic-CLP; PubMed=25877200)
ST   vWA: 14,18 (ATCC)
DI   NCIt; C45663; Pleural sarcomatoid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 35
//
RX   PubMed=7695406; DOI=10.1016/0003-4975(95)00045-M;
RA   Pass H.I., Stevens E.J., Oie H.K., Tsokos M.G., Abati A.D., Fetsch P.A.,
RA   Mew D.J.Y., Pogrebniak H.W., Matthews W.J.;
RT   "Characteristics of nine newly derived mesothelioma cell lines.";
RL   Ann. Thorac. Surg. 59:835-844(1995).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
//
RX   PubMed=16630136; DOI=10.1111/j.1349-7006.2006.00184.x;
RA   Usami N., Fukui T., Kondo M., Taniguchi T., Yokoyama T., Mori S.,
RA   Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T.;
RT   "Establishment and characterization of four malignant pleural
RT   mesothelioma cell lines from Japanese patients.";
RL   Cancer Sci. 97:387-394(2006).
//
RX   PubMed=21245096; DOI=10.1158/0008-5472.CAN-10-2164;
RA   Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T.,
RA   Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H.,
RA   Sekido Y.;
RT   "LATS2 is a tumor suppressor gene of malignant mesothelioma.";
RL   Cancer Res. 71:873-883(2011).
//
RX   PubMed=21642991; DOI=10.1038/ng.855;
RA   Bott M.J., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L.,
RA   Creaney J., Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R.,
RA   Powell S.N., Zhou Q., Shen R.-L., Olshen A.B., Rusch V.W., Ladanyi M.;
RT   "The nuclear deubiquitinase BAP1 is commonly inactivated by somatic
RT   mutations and 3p21.1 losses in malignant pleural mesothelioma.";
RL   Nat. Genet. 43:668-672(2011).
//
RX   PubMed=23830731; DOI=10.1016/j.cancergen.2013.04.006;
RA   Klorin G., Rozenblum E., Glebov O.K., Walker R.L., Park Y.,
RA   Meltzer P.S., Kirsch I.R., Kaye F.J., Roschke A.V.;
RT   "Integrated high-resolution array CGH and SKY analysis of homozygous
RT   deletions and other genomic alterations present in malignant
RT   mesothelioma cell lines.";
RL   Cancer Genet. 206:191-205(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26011428; DOI=10.1111/cas.12698;
RA   Hakiri S., Osada H., Ishiguro F., Murakami H., Murakami-Tonami Y.,
RA   Yokoi K., Sekido Y.;
RT   "Functional differences between wild-type and mutant-type
RT   BRCA1-associated protein 1 tumor suppressor against malignant
RT   mesothelioma cells.";
RL   Cancer Sci. 106:990-999(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28553954; DOI=10.1038/onc.2017.147;
RA   Kato T., Sato T., Yokoi K., Sekido Y.;
RT   "E-cadherin expression is correlated with focal adhesion kinase
RT   inhibitor resistance in merlin-negative malignant mesothelioma
RT   cells.";
RL   Oncogene 36:5522-5531(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//